Breast cancer in moroccan young women: a retrospective study

Show simple item record

dc.contributor.author Benjaafar, Nourddine
dc.contributor.author Abahssain, Halima
dc.contributor.author Lalya, Issam
dc.contributor.author EL M’Rabet, Fatima zahra
dc.contributor.author Ismaili, Nabil
dc.contributor.author Razine, Rachida
dc.contributor.author Tazi, Mohammed Adnane
dc.contributor.author M’rabti, Hind
dc.contributor.author Abouqal, Redouane
dc.contributor.author Errihani, Hassan
dc.date.accessioned 2013-06-25T13:19:12Z
dc.date.available 2013-06-25T13:19:12Z
dc.date.issued 2010-05-27
dc.identifier.issn 1756-0500
dc.identifier.uri http://ao.um5s.ac.ma/xmlui/handle/123456789/315
dc.description.abstract Background: Breast cancer is uncommon in young women and induces more aggressive biologic characteristics. Survival in young women has been widely studied in developed countries. Less favorable prognosis and low survival were found. In Morocco, this study is the first investigation of clinical features, treatment and prognosis associated with breast cancer in young women. Findings: Four hundred and nine women aged 35 years or less were included in this study. All these women were diagnosed as having breast cancer at the National Institute of Oncology in Rabat, Morocco between 2003 and 2007. The relation between clinical and therapeutic characteristics and event-free survival (EFS) and overall survival (OS) were assessed by Cox regression analysis. The median age of the patients was 32 years. Fifty three patients (13%) have metastatic disease at diagnosis and 356 patients (87%) had localised disease. In 57.9% of the cases, the estrogen receptors status was positive. The median follow-up was 32.2 months. After 3 years the survival rate was 80.6%. In the case of localised disease, OS and EFS at 3 years were 83.2% and 62.5%, respectively. OS and EFS at 3 years was higher in patients with stage I than patients with stage II and stage III (p = 0.001). Positive estrogen receptors was significantly associated to OS and EFS at 3 years compared to negative estrogen receptors (p = 0.001). Adjuvant chemotherapy, adjuvant radio- therapy and adjuvant hormone therapy were associated with net benefit in OS and EFS at 3 years. Cox regression analysis showed that negative ER was significantly associated with poorer OS (HR = 2.42, 95% CI = 1.25 - 4.66, p < 0.009) and poorer EFS (HR = 1.73, 95%CI = 1.05 - 2.86, p = 0.03). Stage III disease were associated to poorer EFS (HR = 5.35, 95%CI = 1.60 -17.84, p = 0.006). Conclusions: In Morocco, young women with breast cancer had less favorable prognosis. Multivariate analysis showed that negative hormone receptor status was associated with lower EFS and OS. Clinical trials should be launched to improve the survival of these young women with breast cancer. en_US
dc.language.iso en en_US
dc.publisher BMC Research Notes en_US
dc.title Breast cancer in moroccan young women: a retrospective study en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account